Moderna: token EPS in Q3
(CercleFinance.com) - Moderna reports Q3 2024 EPS of $0.
03, compared with a loss of $9.53 per share a year earlier, with total sales of $1.9bn, compared with $1.8bn in Q3 2023. NB: pmt +9.7%.
Its net product sales rose by 4% to $1.8bn, growth mainly attributable to the US market following the launch of the updated Covid-19 vaccine, while its international sales declined.
For 2024, Moderna reiterates its forecast of net product sales of $3bn to $3.5bn from its respiratory franchise, but now expects only cost of sales of between 40% and 45% of product sales, with R&D expenditure of $4.6bn to $4.7bn.
Management remains focused on supporting sales growth, obtaining 10 product approvals over the next three years, and continuing to reduce our cost structure.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
03, compared with a loss of $9.53 per share a year earlier, with total sales of $1.9bn, compared with $1.8bn in Q3 2023. NB: pmt +9.7%.
Its net product sales rose by 4% to $1.8bn, growth mainly attributable to the US market following the launch of the updated Covid-19 vaccine, while its international sales declined.
For 2024, Moderna reiterates its forecast of net product sales of $3bn to $3.5bn from its respiratory franchise, but now expects only cost of sales of between 40% and 45% of product sales, with R&D expenditure of $4.6bn to $4.7bn.
Management remains focused on supporting sales growth, obtaining 10 product approvals over the next three years, and continuing to reduce our cost structure.
Copyright (c) 2024 CercleFinance.com. All rights reserved.